PROGYNY INC (PGNY) Stock Fundamental Analysis
NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD
Overall PGNY gets a fundamental rating of 7 out of 10. We evaluated PGNY against 108 industry peers in the Health Care Providers & Services industry. PGNY gets an excellent profitability rating and is at the same time showing great financial health properties. PGNY shows excellent growth, but is valued quite expensive already. This makes PGNY very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
PGNY had positive earnings in the past year.
PGNY had a positive operating cash flow in the past year.
Of the past 5 years PGNY 4 years were profitable.
PGNY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.68%, PGNY belongs to the top of the industry, outperforming 92.52% of the companies in the same industry.
PGNY has a Return On Equity of 13.17%. This is amongst the best in the industry. PGNY outperforms 81.31% of its industry peers.
PGNY has a Return On Invested Capital of 12.72%. This is amongst the best in the industry. PGNY outperforms 90.65% of its industry peers.
PGNY had an Average Return On Invested Capital over the past 3 years of 8.61%. This is in line with the industry average of 8.14%.
The 3 year average ROIC (8.61%) for PGNY is below the current ROIC(12.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROIC | 12.73% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
1.3 Margins
PGNY has a Profit Margin of 5.03%. This is amongst the best in the industry. PGNY outperforms 82.24% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
The Operating Margin of PGNY (5.75%) is better than 66.36% of its industry peers.
PGNY's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 21.68%, PGNY is in line with its industry, outperforming 42.99% of the companies in the same industry.
PGNY's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% |
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PGNY is creating some value.
Compared to 1 year ago, PGNY has more shares outstanding
PGNY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.37 indicates that PGNY is not in any danger for bankruptcy at the moment.
PGNY has a Altman-Z score of 8.37. This is amongst the best in the industry. PGNY outperforms 94.39% of its industry peers.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.37 |
ROIC/WACC1.4
WACC9.06%
2.3 Liquidity
A Current Ratio of 2.62 indicates that PGNY has no problem at all paying its short term obligations.
PGNY has a Current ratio of 2.62. This is amongst the best in the industry. PGNY outperforms 82.24% of its industry peers.
PGNY has a Quick Ratio of 2.62. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a better Quick ratio (2.62) than 82.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
PGNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.54%, which is quite good.
PGNY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 97.89% yearly.
PGNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.24%.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 59.52% on average per year.
EPS 1Y (TTM)11.54%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%-31.25%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
3.2 Future
PGNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.33% yearly.
Based on estimates for the next years, PGNY will show a quite strong growth in Revenue. The Revenue will grow by 8.60% on average per year.
EPS Next Y-9.12%
EPS Next 2Y-0.42%
EPS Next 3Y12.52%
EPS Next 5Y31.33%
Revenue Next Year4.94%
Revenue Next 2Y3.01%
Revenue Next 3Y5.79%
Revenue Next 5Y8.6%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.00 indicates a quite expensive valuation of PGNY.
PGNY's Price/Earnings ratio is in line with the industry average.
PGNY's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 29.63.
PGNY is valuated quite expensively with a Price/Forward Earnings ratio of 37.73.
The rest of the industry has a similar Price/Forward Earnings ratio as PGNY.
When comparing the Price/Forward Earnings ratio of PGNY to the average of the S&P500 Index (22.68), we can say PGNY is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40 | ||
| Fwd PE | 37.73 |
4.2 Price Multiples
PGNY's Enterprise Value to EBITDA ratio is in line with the industry average.
89.72% of the companies in the same industry are more expensive than PGNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.32 | ||
| EV/EBITDA | 24.15 |
4.3 Compensation for Growth
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PGNY's earnings are expected to grow with 12.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.42%
EPS Next 3Y12.52%
5. Dividend
5.1 Amount
PGNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.2
-0.68 (-2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.16%
Inst Owner Change-4.53%
Ins Owners6.69%
Ins Owner Change3.22%
Market Cap1.98B
Analysts75
Price Target22.27 (-4.01%)
Short Float %15.95%
Short Ratio6.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.36%
Min EPS beat(2)-19.12%
Max EPS beat(2)-1.61%
EPS beat(4)2
Avg EPS beat(4)6.11%
Min EPS beat(4)-19.12%
Max EPS beat(4)26.05%
EPS beat(8)6
Avg EPS beat(8)48.62%
EPS beat(12)10
Avg EPS beat(12)123.05%
EPS beat(16)13
Avg EPS beat(16)111.27%
Revenue beat(2)0
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-5.35%
Max Revenue beat(2)-2.39%
Revenue beat(4)0
Avg Revenue beat(4)-4.25%
Min Revenue beat(4)-5.82%
Max Revenue beat(4)-2.39%
Revenue beat(8)3
Avg Revenue beat(8)-1.11%
Revenue beat(12)5
Avg Revenue beat(12)-1.25%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)5.3%
PT rev (3m)-16.27%
EPS NQ rev (1m)3.1%
EPS NQ rev (3m)-44.64%
EPS NY rev (1m)0.73%
EPS NY rev (3m)-22.2%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)-15.26%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-2.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40 | ||
| Fwd PE | 37.73 | ||
| P/S | 1.73 | ||
| P/FCF | 12.32 | ||
| P/OCF | 12 | ||
| P/B | 4.54 | ||
| P/tB | 4.73 | ||
| EV/EBITDA | 24.15 |
EPS(TTM)0.58
EY2.5%
EPS(NY)0.61
Fwd EY2.65%
FCF(TTM)1.88
FCFY8.12%
OCF(TTM)1.93
OCFY8.33%
SpS13.37
BVpS5.11
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROCE | 14.5% | ||
| ROIC | 12.73% | ||
| ROICexc | 26.63% | ||
| ROICexgc | 28.94% | ||
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% | ||
| FCFM | 14.09% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
ROICexc(3y)19.38%
ROICexc(5y)20.33%
ROICexgc(3y)20.85%
ROICexgc(5y)26.41%
ROCE(3y)9.81%
ROCE(5y)9.05%
ROICexcg growth 3Y24.58%
ROICexcg growth 5YN/A
ROICexc growth 3Y31.27%
ROICexc growth 5YN/A
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
F-Score7
Asset Turnover1.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 139.02% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 240.38% | ||
| Profit Quality | 280.06% | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 8.37 |
F-Score7
WACC9.06%
ROIC/WACC1.4
Cap/Depr(3y)175.37%
Cap/Depr(5y)143.9%
Cap/Sales(3y)0.39%
Cap/Sales(5y)0.55%
Profit Quality(3y)196.21%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.54%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%-31.25%
EPS Next Y-9.12%
EPS Next 2Y-0.42%
EPS Next 3Y12.52%
EPS Next 5Y31.33%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
Revenue Next Year4.94%
Revenue Next 2Y3.01%
Revenue Next 3Y5.79%
Revenue Next 5Y8.6%
EBIT growth 1Y26.63%
EBIT growth 3Y89.07%
EBIT growth 5YN/A
EBIT Next Year128.4%
EBIT Next 3Y37.05%
EBIT Next 5Y26.82%
FCF growth 1Y363.59%
FCF growth 3Y73.98%
FCF growth 5Y155.82%
OCF growth 1Y336.49%
OCF growth 3Y73.42%
OCF growth 5Y142.1%